BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Macular degeneration and retinal disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for macular degeneration: 209 (134 sponsors; 31 newly posted in the last 180 days, 2 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 17.2, rank 35 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 5, Phase 1 26, Phase 2 70, Phase 3 50, Phase 4 4, N/A 54.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Hoffmann-La Roche9NA 3, P3 4, P4 1, P2 102
AbbVie ABBV7P2 4, P3 301
Kodiak Sciences Inc KOD3P3 302
Ocular Therapeutix, Inc. OCUL3P3 301
Adverum Biotechnologies, Inc.5P2 2, P3 2, NA 111
4D Molecular Therapeutics FDMT3P3 2, P2 101
EyeBiotech Ltd.3P3 2, P2 100
Ocugen OCGN3P2 1, P3 210
Regeneron Pharmaceuticals REGN3P1 1, P3 200
Annexon, Inc. ANNX2P3 210
Belite Bio, Inc BLTE2P3 200
EyePoint Pharmaceuticals, Inc. EYPT2P3 200
Merck Sharp & Dohme LLC MRK new entrant2P3 220
Ollin Biosciences, Inc. new entrant2P3 220
Alkeus Pharmaceuticals, Inc.3P2 2, P3 100
Innostellar Biotherapeutics Co.,Ltd3P2 1, P3 1, P1 100
Amgen AMGN new entrant1P3 110
AO GENERIUM new entrant1P3 110
BioDlink Biopharm Co., Ltd.1P3 100
Innovent Biologics (Suzhou) Co. Ltd.1P3 101
Janssen Research & Development, LLC1P3 100
Mighty Therapeutics Inc. new entrant1P3 110
Outlook Therapeutics, Inc. OTLK1P3 100
Qilu Pharmaceutical Co., Ltd.1P3 101
RemeGen Co., Ltd. new entrant1P3 110

New-entrant sponsors: Merck Sharp & Dohme LLC, Ollin Biosciences, Inc., Amgen, AO GENERIUM, Mighty Therapeutics Inc., RemeGen Co., Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2/P3AbbVie ABBVNCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Agactive not recruiting671
2026-12 est.P2jCyte, IncNCT06912633 Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)Retinitis Pigmentosaactive not recruiting31
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT07489586 A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)not yet recruiting356
2026-12-01 est.P3Shanghai Vitalgen BioPharma Co., Ltd.NCT06699108 Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline DystrophyBietti Crystalline Dystrophy; Inherited Retinal Diseasesactive not recruiting45
2026-12-22 est.P3Adverum Biotechnologies, Inc.NCT06856577 Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD); Wet AMDactive not recruiting311
2026-12-28 est.P1/P2Chengdu Origen Biotechnology Co., Ltd.NCT05672121 Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)Age-Related Macular Degenerationrecruiting42
2026-12-30 est.P1/P2Bionic Sight LLCNCT04278131 BS01 in Patients With Retinitis PigmentosaRetinitis Pigmentosarecruiting20
2026-12-31 est.P2Innovent Biologics Technology Limited (Shanghai R&D Center)NCT06908876 A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)Diabetic Macular Oedemaactive not recruiting150
2027-01 est.P1/P2Skyline Therapeutics (US) Inc.NCT05986864 Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular Degenerationrecruiting68
2027-01-08 est.P3Ocular Therapeutix, Inc. OCULNCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNeovascular Age-related Macular Degenerationactive not recruiting825
2027-01-11 est.P2/P3EyeBiotech Ltd.NCT06957080 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)active not recruiting1054
2027-01-31 est.P3iRenix Medical, Inc.NCT05750589 Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal InjectionsRetinal Diseasenot yet recruiting240
2027-02 est.P1/P2SparingVisionNCT05748873 Promising ROd-cone DYstrophy Gene therapYRetinitis Pigmentosaactive not recruiting33
2027-02 est.P3Kodiak Sciences Inc KODNCT06996080 A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLEMacular Edema Secondary to Inflammationrecruiting300
2027-02-04 est.P3Hoffmann-La RocheNCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular AgeNeovascular Age-related Macular Degeneration (nAMD)active not recruiting451
2027-02-07 est.P1/P2Intra-IMMUSG Pte LtdNCT07547228 A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age Related Macular Degenerationrecruiting15
2027-02-12 est.P3Ocugen OCGNNCT06388200 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaRetinitis Pigmentosaactive not recruiting140

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2SciNeuroNCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME PatientsDiabetic Macular Edema; DMEnot yet recruiting60
2026-11 est.P2Kiora Pharmaceuticals, Inc. KPRXNCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaMacular Edemarecruiting28
2026-10-31 est.P2Neurimmune AGNCT07213583 Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMAmyloid Transthyretin Cardiomyopathyactive not recruiting35
2026-10-31 est.P2Kyowa Kirin Co., Ltd.NCT06116916 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaDiabetic Macular Edema (DME)active not recruiting185
2026-10-26P2Boehringer IngelheimNCT06722157 A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyMacular Degeneration, Age-related; Geographic Atrophycompleted202
2026-10-15 est.P1/P2Eclipse Life Sciences, Inc.NCT06536491 EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaDiabetic Macular Edemaactive not recruiting75
2026-10-13P2AbbVie ABBVNCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD)active not recruiting146
2026-10-01P2Qlaris Bio, Inc.NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel DilationNon-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (Ncompleted9
2026-10 est.P3AbbVie ABBVNCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNVactive not recruiting735
2026-09-30 est.P2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339 Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDWet Age-related Macular Degeneration (wAMD)not yet recruiting40
2026-09-22P2Samsung Bioepis Co., Ltd.NCT07844343 A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular OedemaNeovascular Age-related Macular Degeneration; Macular Oedema Secondary to RVO; Diabetic Macular Oedecompleted33
2026-09-09P3EyePoint Pharmaceuticals, Inc. EYPTNCT06683742 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-09-02P3Kodiak Sciences Inc KODNCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-reWet Age-related Macular Degenerationactive not recruiting667
2026-09 est.P3Rophibio, Inc.NCT06470373 A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration (nAMD)not yet recruiting434
2026-09 est.P3Salutaris Medical Devices, Inc.NCT05251636 Adjunct Episcleral Brachytherapy for PCVAge-Related Macular Degeneration; Polypoid Choroidal Vasculopathynot yet recruiting159
2026-09 est.P3Eidos Therapeutics, a BridgeBio companyNCT04882735 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathywithdrawn
2026-08-30 est.P2Innovent Biologics Technology Limited (Shanghai R&D Center)NCT07275840 A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMDNeovascular Age-related Macular Degenerationrecruiting800
2026-08-30 est.P3Beletalent (Zhuhai) Pharmaceutical Co., LtdNCT06817265 Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic RetinopathyNon-Proliferative Diabetic Retinopathyrecruiting360
2026-08-25P1/P2Hoffmann-La RocheNCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationMacular Degenerationcompleted177
2026-08-19P2Novartis Pharmaceuticals NVSNCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationAge-Related Macular Degenerationcompleted168
2026-08-12P2EnnovaBioNCT06708260 A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DMEDiabetic Macular Edema (DME)completed60
2026-07-31 est.P2OHB Neonatology Ltd.NCT03253263 A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsBronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage; Retinoactive not recruiting295
2026-07-14P2/P3EyeBiotech Ltd.NCT06571045 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEDiabetic Macular Edema (DME)active not recruiting984
2026-07-13P3EyePoint Pharmaceuticals, Inc. EYPTNCT06668064 A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Wet Age Related Macular Degeneration; wAMDactive not recruiting400
2026-07 est.P2Annexin Pharmaceuticals ABNCT07259928 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionNon-Proliferative Diabetic Retinopathy; Retinal Vein Occlusionrecruiting12
2026-06-30 est.P2/P3Beacon Therapeutics BBTNCT04850118 A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPX-Linked Retinitis Pigmentosaactive not recruiting85
2026-06-18P2AbbVie ABBVNCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)completed139
2026-06-03P2Kyowa Kirin Co., Ltd.NCT06116890 Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)completed170
2026-06 est.P3RemeGen Co., Ltd.NCT05885503 Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaDiabetic Macular Edemaunknown316
2026-06 est.P1/P24D Molecular Therapeutics FDMTNCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)X-Linked Retinitis Pigmentosaactive not recruiting21
2026-05-27P2Sam Chun Dang Pharm. Co. Ltd.NCT07501052 Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or DiabeticNeovascular (Wet) Age-Related Macular Degeneration; Retinal Vein Occlusion; Diabetic Macular Edema; completed33
2026-05-27P1/P2Elisigen, Inc.NCT05984927 NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular DegenerationAge-Related Macular Degenerationactive not recruiting20

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "macular degeneration"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.